

Disclaimer



The information contained in this presentation is for information purposes only and does not constitute an offer or invitation to sell or purchase for share in Saintmed Public Company Limited ("SMD"). No part of this presentation shall be relied upon directly or indirectly for any investment decision-making for any purposes.

This presentation may include information which is forward-looking based on management's current views and assumption including, but not limited to, prevailing economic and market conditions. These statements involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ from the results, performance or achievements expressed or implied by such forward-looking statements. Such statements are not, and should not be constructed as representation as to future performance of SMD. In particular, such targets should not be regarded as a forecast or projection of future performance of SMD. It should be noted that the actual performance of SMD may vary significantly from such targets.

SMD makes no representation as to the accuracy or completeness of such information or otherwise provided by SMD. Prior to acting on any information contained herein, the receiver should determine the risks and consequences, without reliance on SMD.





Business Recap

• Q3/2023 Key Financial Performance

Medical Devices Industry Outlook

SMD Business Outlook





SAINTMED

Investing for financial returns while also contributing to the public healthcare system









Business Recap



SMD is a distributor of medical devices from more than 30 international manufacturers and provides various services to customers.





Business Recap — Dividend payment



On 14 November 2023, the Board of Directors has approved to pay interim dividend. The details as follows: -

Dividend type: Cash dividend

• **Record date:** 29 November 2023

Ex-dividend date (XD): 28 November 2023

• **Payment rate:** 0.15 baht per share

Par value of the share: 0.50 baht

• Payment date: 13 December 2023

Historical dividend payment

(unit: baht)



^{*} Dividend policy is not paying lower than 30% of net profit after deduction of tax and all reserves as required by law (with additional conditions)

Business Recap – Share Repurchases for Financial Management



On 23 September 2023, the Board of Directors has approved to launch a share repurchases program. The Company is pleased to update the current of processing on this program, details as follows: -

	Condition as approved by the BOD	Status (as of 20 Nov 2023)
Max. amount to repurchase:	< THB 120mn	Total of 14,452,182 baht
Max. shares to repurchase:	< 22mn shares (not more than 9.79% of total issued shares)	2,957,400 shares 1.32%
The repurchasing method:	Through the SET	
Period of the repurchasing:	within 6 months (during 9 October 2023 – 30 March 2024)	




Q3/23 Key
Financial
Performance




Key Financial Performance









Revenue Breakdown by Customers




Sales Revenue Breakdown by Product Groups






Key Financial Performance

SG&A and SG&A to Revenues



NOPAT and Margins



SG&A still constant in each quarter but lower revenue resulted in high SG&A to Revenue

SG&A

declined by -4.0% YoY and -12.2% QoQ in Q3/2023

SG&A to Revenues

is 27.0% in Q3/2023 (compared to 11.6% in Q3/2022)

Selling Expenses

decreased by -5.7% YoY but increased 5.9% QoQ in Q3/2023

General Administrative Expenses


decreased by -1.5% YoY and -29.3% QoQ in Q3/2023

Net Operating Profit After Tax (NOPAT) and Margins

- NOPAT Q3/2023 Decreased 82.1% YoY resulting from the decline in the general medical devices group compared to Q3/2022 and decreased 57.2% QoQ
- NOPAT Margin in Q3/2023 is 6.7%, resulting from the decrease in sales but operating and fixed costs are not lower as sales.

Key Financial Performance





Q3/2023 compare to FY2022

Assets Decreased by 5.6%

Cash & Deposits >> Decrease

Liabilities Decreased by -2.5%

• Short-Term Loans = 0, Long-Term Loans = 0

Equities Decreased by -6.2%

• Due to retained earnings and dividend payment

Key Financial Ratio	Q3/23	FY22
Asset Turnover (x)	0.51	1.66
AR Days	75.16	22.67
AP Days	58.86	12.71
Inv Days	183.08	65.41
Cash Cycle Days	199.38	75.37
D/E (x)	0.18	0.18
	Q3/23	FY22
ROA	5.70%	24.51%
ROE	6.76%	28.86%



MEDICAL DEVICES
INDUSTRY OUTLOOK

& KEY FACTORS
AFFECTING
SMD PERFORMANCE



Q3/2023 key factors affecting SMD performance





Aging Society

(+) An aging population is increasing. Positive impact for sleep test services, CPAP products and increasing demand for NCDs medical devices.





Medical Tourism

(+) positive impact on increasing demand for medical devices which made for treatment complex disease.





Preventive Care Trends

(+) key to helping people stay healthy and detecting health problems early on, before they cause other issues or become more difficult to treat.





Demand for ATK Products

(-) Decline demand from the increase in the percentage of vaccinated people and the post-pandemic situation of COVID-19.




Industry Outlook – AGING Society




NCDs and Complex diseases

An aging population is often associated with an increased risk of non-communicable diseases (NCDs) such as cardiovascular disease, diabetes, and cancer.








Industry Outlook – Fiscal Budget of Ministry of Public Health



Continuously Growing with Fiscal Budget of Ministry of Public Health



The Fiscal Budget of the Ministry of Public Health is growing constantly and predictably.

Source: moph.go.th thaime.nesdc.go.th

15



SMD BUSINESS OUTLOOK





Critical Care Products





























Sleep Medicine Products



Cardiology Products











General MedicalDevice Products











Smart Hospital and Al Products













Wellness Products



Business Outlook – SleepLab



Sleep Lab

- Sleep Lab generated revenue of **3.47 MB** in Q3/23 (+91% YoY) (+26% QoQ)
- Occupancy rate (4 beds) was **70-80%** in Q3/23
- SMD has signed a contract for sleep test devices rental service for 3 years period at the Faculty of Medicine Ramathibodi Hospital (contract signed 27/01/2023)

Sleep Test Revenue (Millions THB)



Noted: Not include device sales







Business Outlook - Long Term Business Plan "ServeHealth"



- a subsidiary company "ServeHealth"
- Company Objective: Rental, hire-purchase, leasing of the medical equipment, medical vehicle, and wellness equipment services.
- To strengthen potential in business competition and sustainability.






Outlook - Backlog



213 MB of backlogs (As of Sep 30, 2023)



26



SAINTMED

Sleep Medicine

Critical Care

Cardiology

PRODUCT GROUPS Smart

Q&A

For more information, please contact IR department

General Medical Device IR@saintmed.com Tel: 06 3224 6722

